Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris.

Abstract

The effect of nicorandil, a new coronary vasodilator, was evaluated in 32 patients with variant angina pectoris in a single-blind trial. The study was comprised of a pretreatment period of 2 days with a placebo, a 3-day nicorandil medication period (20 mg/day), and a 2-day posttreatment period with the placebo. Anginal attacks disappeared completely in 24 of the 32 patients. The number of attacks during the pretreatment period, 3.6 +/- 0.4 per day, became significantly reduced to 0.7 +/- 0.2 per day during nicorandil therapy (P less than 0.001) and significantly increased to 1.3 +/- 0.3 per day after withdrawal of the drug (P less than 0.05). In 17 patients with continuous ECG monitoring, the frequency of occurrence of ST-segment elevation was 8.6 +/- 2.7 per day during the preobservation period, significantly decreased to 0.4 +/- 0.2 per day during nicorandil therapy (P less than 0.01), and significantly increased to 1.9 +/- 0.7 per day after withdrawal of the drug (P less than 0.05). The results demonstrate the effectiveness of nicorandil in the treatment of variant angina pectoris.

• Authors: H Kishida, S Murao
• Journal: Clinical pharmacology and therapeutics (Clin Pharmacol Ther) Vol. 42 Issue 2 Pg. 166-74 (Aug 1987) ISSN: 0009-9236 [Print] United States
• PMID: 2955996 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Vasodilator Agents
• Niacinamide
• Nicorandil

Topics

• Angina Pectoris, Variant (drug therapy)
• Clinical Trials as Topic
• Electrocardiography
• Female
• Humans
• Male
• Middle Aged
• Monitoring, Physiologic
• Niacinamide (analogs & derivatives, pharmacology, therapeutic use)
• Nicorandil
• Time Factors
• Vasodilator Agents (pharmacology, therapeutic use)